摘要
酪氨酸抑制剂的应用革命性地改变了慢性髓系白血病(CML)患者的生存及预后,当前CML治疗已发生了新的改变,越来越多的患者追求更深层次分子学缓解,以减少耐药复发,追求无治疗缓解和功能性治愈。目前获批上市的各种TKI均各有优劣,并且不断有新型TKI药物研发以及进行临床试验,现对各种TKI药物治疗CML患者进行综述。
The application of tyrosine inhibitors has revolutionized the survival and prognosis of patients with chronic myeloid leukemia.The current treatment of CML has undergone new changes.More and more patients are pursuing deeper molecular remission to reduce drug resistance recurrence,and pursuing no treatment remission and functional cure.Currently,various TKI approved for marketing have their own advantages and disadvantages,and new TKI drugs are constantly being developed and clinical trials are being conducted.Now,various TKI drugs for CML patients are reviewed.
作者
杨青
葛晓燕
YANG Qing;GE Xiaoyan(The second Clinical Medical College of Shanxi Medical University,Taiyuan 030001,China;The Second Hospital of Shanxi Medical University,Taiyuan 030001,China)
出处
《中国全科医学》
北大核心
2023年第S01期104-108,共5页
Chinese General Practice
